A Culture of Continuous Quality Improvement Improves Registry Data  by Minas, Nicolette Maria & Ruehle, Kathleen
Abstracts / Biol Blood Marrow Transplant 19 (2013) S167eS177 S169Conclusions: Both gE/AS01B and gE/AS01E formulations and
both schedules were immunogenic and well tolerated in
autologous HCT recipients.Table 1
Etanercept arm Placebo arm p
Day 28 Response 62.5% (95%CI:
35.4-84.8)
66.7% (95%CI: 41.0-86.7) .80
Day 56 Response 56.3% (95%CI:
29.9-80.3)
50.0% (95%CI: 26.0-74.0) .72
6 month OS 50.0% (95%CI:
24.5-71.0)
33.3% (95%CI: 13.6-54.5)
Median survival 171 days (95%CI:
11-362)
64 days (95%CI: 26-209)
Log-rank (OS) .51108
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IPS is a frequently fatal form of non-infectious pneumonia
occurring early after allogeneic SCT. We conducted a phase III
trial to investigate if a soluble TNF binding protein, etanercept
(Enbrel Amgen), when givenwith corticosteroids, improved
management of IPS. The study was supported by the NHLBI
andNCI,with etanercept supplied byAmgen. Eligible patients
were 18 yrs, within 180 days post allo-SCT, with diffuse
pulmonary inﬁltrates, and absence of active infection, sepsis
syndrome, or cardiogenic shock. A negative BALwas required
at study entry. Patients were randomized to receive eta-
nercept (0.4 mg/kg/dose 2x/week x 4 weeks) or placebo, in
addition to corticosteroids (2.0mg/kg/day,with taperallowed
after 7 days). Response was deﬁned as survival with discon-
tinuation of supplemental oxygen for>72 hours by day 28 of
study. The trial was initially designed to enroll 120 patients,
with sufﬁcient power to identify a 25% response difference
(30% to 55%) between study arms. Due to suboptimal accrual,
inclusion criteria were modiﬁed and expected enrollment
decreased to 60 patients, 30 per arm. The trial did not meet
accrual goals and was stopped after enrolling 34 patients.
Results: Between 2007 and 2011, 34 patients (median age
46.6y, range 22-70 y) were randomized to receive etanercept
(n¼16) or placebo (n¼18). Study arms were balanced for
patient demographics, except for a higher incidence of AML in
the placebo arm (50% vs 6%, P ¼ .02). 50% of etanercept and
55% of placebo treated patients received all intended study
doses, whereas 38% of etanercept and 6% of placebo treated
patients received 25% of intended dosing (primarily inves-
tigator discretion). Response at day 28 and day 56, and overall
survival were comparable between groups (Table 1). There
were no differences in time to discontinuation of supple-
mental oxygen, incidence of grades 3-5 adverse events,
infections, cumulative incidence of relapse, or grades 2-4or 3-
4 acute GVHD. Patients receiving 40% FiO2 at study entry
had response rates of 91% (placebo) and 73% (etanercept)respectively. By comparison, responses in patients receiving
>40% FiO2 at entry were 17% (1 of 6) on the placebo arm and
50% (2 of 4) on the etanercept arm.
Conclusion: No improvement in response or survival was
noted when etanercept was added to corticosteroids for the
treatment of IPS, though the small sample size signiﬁcantly
limits the statistical power of this study. Compared to
historical reports, the response to corticosteroids alone was
higher than anticipated supporting the importance of
studying controls when evaluating a new therapy.TRANSPLANT DATA MANAGEMENT ORAL109
A Culture of Continuous Quality Improvement Improves
Registry Data
Nicolette Maria Minas, Kathleen Ruehle.. University of
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Background: To ensure the highest degree of accuracy of
CIBMTR (Center for International Blood and Marrow Trans-
plant Research) data, the University of Maryland Blood and
Marrow Transplant team established a culture of continuous
quality improvement. In early 2012, Minas and Ruehle re-
ported the signiﬁcance of auditing 10 commonly used data
collection points. Since that time, their program set out to
identify additional data points of signiﬁcance.
Methods: The Blood and Marrow Transplant Program
Manager and Data Managers continued to evaluate the
quality of their data by selecting 19 additional data points for
audit to assess the signiﬁcance of adding these additional
data points to the 10 commonly used ones. The CIBMTR
forms of four subjects per month (40%) were randomly
selected for audit from August 2011 to August 2012, for
a total of 48 charts.
Results: Our results demonstrated that adding the extra data
points covers 90% of the data reported while the commonly
used data points cover only 50% of the data reported; thereby
demonstrating a more comprehensive review of the infor-
mation reported. Implementing the regular internal audit
using the 10 commonly used data points demonstrated
better percentage (range 89% to 100%) of data accuracy from
that previously reported before implementing the regular
internal audit. When the 19 additional data points were
reviewed as a whole, there was a 96% accuracy rate.
Corrective action was taken by reviewing all CIBMTR forms
with less than 100% accuracy rate and correcting the data in
the electronic database. Education is given on the individual
level and for the group as trends become prevalent.
Conclusion: Implementing internal audits on a regular basis
using the commonly used data points and the additional 19
data points have improved the accuracy of the data from
what has been previously reported. By maintaining
Abstracts / Biol Blood Marrow Transplant 19 (2013) S167eS177S170a regularly scheduled comprehensive review, we are able to
track trends on an individual and group basis. Therefore,
developing new methods to improve our data prepares us
better for challenges of external audits, such as CIBMTR and
FACT (Foundation for the Accreditation of Cellular Therapy).
N.M. Minas, K. Ruehle. CIBMTR Monthly Internal Assess-
ment Improves Quality of Registry Data. Biology of Blood and
Marrow Transplantation. Volume 18, Issue 2, Supplement,
Page S239, February 2012 [abstract].
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Signature Authentication
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Introduction: The written signature as a validation tool has
not kept up with the electronic age. Written signatures are
cumberson, difﬁcult to verify, easy to forge or pre date, and
inﬂexible for staff.
The clinicians signature is a requirement of multiple
accrediting bodies (most notably the Foundation for the
Accreditation of Cellular Therapy), and is needed for internal
and external written agreements, audits, validations, SOPs,
orders and consents. The handwritten signature is an inef-
ﬁcient use of time and with multiple items needed for
signature can be extremely cumbersome. The DM and QM
staff must wait for the document to be reviewed, (either in
the moment or leave the document with the clinician and
keep checking back for completion). The handwritten
signature can be easily forged or pre-dated making its
authenticity questionable.
Due to these factors an electronic signature was imple-
mented in our program using an Adobe digital signature
program. This change was reviewed with our legal depart-
ment and accrediting bodies who determined this was an
acceptable, and preferable, format. The change was as simple
as changing preferences electronically and was able to be
communicated to staff through a mass email. Next, the
documents to be signed were converted to PDF ﬁle format.
Those ﬁles were then sent electronically to the signator/s.
The signator/s then reviewed the documents at their leisure
and returned the document to the originator with the elec-
tronic signature applied.
The PDF format of the document ensures that the infor-
mation contained has not been altered. The electronic
signature uses encryption technology to verify the signer's
digital identity. The signature consists of three components,
each of which can be customized; the signature, signature
details (e.g. an email address or business location), and
a watermark. Each signature includes the real time and date
that the signature was applied making post or pre dating
impossible.
Example:
Conclusion: Workﬂow was dramatically improved with
electronic submission, review, and return of all documents
providing increased ﬂexibility on the part of the staff. There
is a new integrity and authenticity to the signatures due toa higher level of security thru the use of encryption and the
use of a real time and date stamp. Staff, auditors, and
inspectors alike can be assured they are viewing the most
current, authentic, version of any document by reviewing the
signature stamp.
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Background: Reporting to the Center for International Blood
and Marrow Transplant Research (CIBMTR) and internal
databases requires process management to ensure accurate
data, validity, reliability, error rate, and outcomes. Status quo
processes that go unchallenged remain inefﬁcient and costly.
Updating our process and targeting best practices has
reduced our critical ﬁeld error rate from 4.2% to 1.7% (CIBMTR
audit, 2008 e 2012). We recommend ﬁve innovative process
areas BMT research centers can begin implementing today
with the goal of continuous process improvement.
Five Areas for Innovation: We are targeting innovation in
the following areas: (a) Technology, (b) Communication (c)
Work ﬂow, (d) Stafﬁng, and (e) Data Reliability.
Technology:
 Converting traditionally paper processes into electronic
data ﬁles and scanning documents into our electronic
medical record.
 Rethinking data storage has increased data security and
saved the department an estimated $934.00 per year.
Communication:
 Establishing standardized internal data collection
forms and information sharing encouraged trans-
parency throughout the clinical team.
 Targeting processes including: lost to follow-up,
CIBMTR research consent, comorbidities and infections,
and Physician sign-off.
Work Flow:
 Identifying both low cost and efﬁcient solutions to
workﬂow barriers.
 Redeﬁning tasks for better time tracking, project
management, and Data Coordinator (DC) training.
 Using student interns to address long term data storage
projects.
Stafﬁng:
 Avoiding costly bad hires and reducing turnover by
selecting DC's with strong research backgrounds.
 Conducting peer interviews to gauge personality ﬁt
with the current research team.
Data Reliability:
 Preventing errors with a multi-level checks and
balances procedure for DC feedback.
 Developing internal training manuals with mutually
exclusive and exhaustive categories to eliminate
disagreements in data coding and entry.
 Future reliability testing to streamline DC training and
increase validity. An intercoder reliability above 80%
will be considered acceptable (Krippendorf, 2007).
